 "Animal vaccine")
Preliminary data released by Cadila Healthcare (Zydus Cadila) from animal trials show that their DNA-plasmid vaccine candidate ZyCoV-D has induced immune response in multiple animals. Apart from generating neutralising antibodies post vaccination, the vaccine candidate has also induced T-cell response, claimed the firm. (T cells are central players in the immune response to viral infection.)
Furthermore, the stability data showed that ZyCoV-D can be stored at 2 to 8 degrees Celsius for the long term and at 25 degrees Celsius for short term (a few months). The vaccine is in phase 3 clinical trials in India with over 30,000 people.
Being able
